Pioneering breakthroughs in mineral-driven pathologies to reverse clinical decline and address critical unmet needs.
Petragen’s therapeutic platform is focused on the direct physical pathophysiology of mineralization-related diseases—not on a distant target somewhere in a signaling pathway that may carry conflicting or competing biological signals. By targeting the mechanism at the point where disease actually occurs, we aim to develop therapies that are precise, predictable, and meaningfully disease-modifying. Our programs span conditions with large unmet need and limited current options, from common diseases affecting tens of millions to rare inherited disorders where treatment burden remains unacceptably high.
One of the most common diseases affecting nearly 36 million people in the U.S. alone. Current treatments have minimal benefit, offering fractions of a millimeter improvement in key clinical endpoints like pocket depth. Petragen believes it can be best in class for this large and underserved indication.
Explore Periodontal disease →
A rare inherited metabolic disease that can affect bone and dental health. Current biological treatments can cost up to $2 million per year and require near daily injections. Petragen believes its small molecule solution can relieve the injection burden for patients while bringing costs down dramatically.
Explore HPP →
A crystal arthropathy that affects nearly 10 million people in the U.S., with limited disease-modifying options. Petragen sees this as an opportunity to have an impact on the direct pathophysiology while staying within the modality that patients and physicians are used to.
Explore CPPD →Petragen’s leadership team brings over 140 years of combined experience across drug development, life science management, business development, clinical periodontal practice, and translational research. This depth of expertise spans discovery through commercialization and positions the company to execute with rigor at every stage.
We welcome conversations with strategic investors, development partners, and scientific collaborators aligned with our mission.
Partner With Us